APA (7th ed.) Citation

Chauhan, A., Reis, I., Jani, C., Modak, R., Bilbao, D., Merchan, J., . . . Trinh, H. (2025). 1733TiP A phase I trial of the oncolytic virus SVV-001 in combination with nivolumab and ipilimumab in patients with poorly differentiated neuroendocrine carcinomas or well-differentiated grade 3 neuroendocrine tumors. Annals of Oncology, 36, S1019. https://doi.org/10.1016/j.annonc.2025.08.2361

Chicago Style (17th ed.) Citation

Chauhan, A., et al. "1733TiP A Phase I Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas or Well-differentiated Grade 3 Neuroendocrine Tumors." Annals of Oncology 36 (2025): S1019. https://doi.org/10.1016/j.annonc.2025.08.2361.

MLA (9th ed.) Citation

Chauhan, A., et al. "1733TiP A Phase I Trial of the Oncolytic Virus SVV-001 in Combination with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas or Well-differentiated Grade 3 Neuroendocrine Tumors." Annals of Oncology, vol. 36, 2025, p. S1019, https://doi.org/10.1016/j.annonc.2025.08.2361.